Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: FranciaországFázis nélkül

Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders

A legfontosabb adatok

Ki végzi
University Hospital, Montpellier
Hol
Montpellier (Franciaország)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
7320 fő, tervezett
Kezdés
2023. ápr. 19.
Várható befejezés
2034. márc.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • Questionnaires
  • Biospecimen collection
  • Neurodevelopmental assessment visit
  • DNA collection
A regiszteradat frissítve
2026. június 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan családokat keres, akik egy új terhesség elején járnak. Egyes családoknak már van autizmussal élő gyermeke, másoknál nincs ismert kockázat.

Életkor
Anya és apa: legalább 18 éves. Autizmussal élő gyermek: legalább 24 hónapos és 18 évnél fiatalabb.
Nem
Minden nem részt vehet.
A betegség stádiuma
Magas kockázatú csoport: a családban van gyermek igazolt autizmus spektrum zavar diagnózissal. Alacsony kockázatú csoport: nincs autizmussal vagy más idegrendszeri fejlődési zavarral élő gyermek.

A részvétel fő kizáró okai

  • Nem érti a francia nyelvet vagy a vizsgálat kérdőíveit
  • Jogi védelem alatt áll (gondnokság) vagy a szabadságától megfosztották
  • Nincs társadalombiztosítási rendszerhez tartozás
  • Túl messze lakik a felvételi központtól a követéshez
  • Alacsony kockázatú csoport: van autizmussal vagy más idegrendszeri fejlődési zavarral élő biológiai gyermeke

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • General inclusion criteria (High risk and Low risk cohorts)
  • Mother:
  • Be pregnant (single or multiple pregnancy), at least 16 weeks of amenorrhea,
  • Have at least one biological child of 24 months or older,
  • At least 18 years of age; Father:
  • Be the biological father of the unborn child,
  • At least 18 years of age; Unborn Child:
  • Have a woman study participant as mother; Specific inclusion criteria for the High risk cohort:
  • Autistic sibling: refers to the biological child(ren) of the mother and/or father participating in the study and being the parent(s) of the unborn child
  • Be at least 24 months old and less than 18 years old,
  • Have a confirmed diagnosis of Autism Spectrum Disorder based on medical records. If in doubt, the SRS-2 (Social Responsiveness Scale for Adults) and PEDS-DM (Parents' Evaluation of developmental status) questionnaires will be completed. Only children with positive scores on one of these questionnaires will be included after validation of the diagnosis by an expert committee,
  • In case of several children with Autism Spectrum Disorder based in the siblings, only the last born will be included; Remarks:
  • Autism Spectrum Disorder siblings resulting from a medically assisted procreation are eligible provided that part of the genetic heritage is common to that of the mother or father of the unborn child participating in the study
  • If the father does not live with the mother of the unborn child, his participation is not required and does not preclude the participation of other family members

Ki nem vehet részt

  • Have a biological child with a diagnosis of Autism Spectrum Disorder or other neuro developmental disorder
  • General non-inclusion criteria (High risk and Low risk cohorts):
  • Father and mother:
  • Unable to understand French or the study questionnaires
  • Participant on protective measures (guardianship or curatorship) or deprived of liberty by judicial or administrative decision, or subject to a legal protection measure
  • Not affiliated to a social security system
  • Refusal to participate. In the case of consent given for the born and unborn child, the consent must be given by the person(s) with parental authority
  • Live at a distance from the recruitment center incompatible with follow-up; Specific non-inclusion criteria for the Low risk cohort:; Mother and/or father of unborn child:

Helyszínek itt: Franciaország

  • CHU MontpellierMontpellier, FranciaországContact: Amaria BAGHDADLIRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Neurodevelopmental disorders such as attention deficit disorder with or without hyperactivity, autism spectrum disorder, language and social communication disorder, motor coordination disorder, learning disorder (dyslexia, dyscalculia, dysorthography), intellectual development disorder are frequent and long-lasting developmental difficulties that can be observed in children in various domains. They are often associated and have a significant impact on daily functioning at school and at home.

A teljes eredeti leírásKevesebb

The rate of people affected by neurodevelopmental disorders including autism spectrum disorder have increased significantly over the past 20 years. Improved screening only partly explains this evolution.

A genetic predisposition plays an important role in the occurrence of these disorders, however, current scientific data suggest a multifactorial origin. Exposures such as those related to the use of pesticides, air pollution or the presence of endocrine disruptors in our diet could be involved in the genesis of neurodevelopmental disorders, particularly during intrauterine life, a period of great vulnerability.

The current diagnostic pathways for autism rarely enable the early identification of babies at risk. Without early detection and timely targeted intervention, these children have a poor health outcome and do not reach their full potential.

The general objective of the MARIANNE cohort is to constitute a French research infrastructure dedicated to research on the biological and environmental determinants of neurodevelopmental disorders including autism.

This cohort is based on the follow-up of 1200 families with already a child affected by an autism spectrum disorder, which implies a high risk of neurodevelopmental disorders including autism spectrum disorder for the siblings, and of 500 families from the general population with no excess risk of neurodevelopmental disorders. The total number of subjects to be included (mother, father, unborn child and ASD sibling for the HR group) is thus 6300.

The inclusion of these families will be at the beginning of a new pregnancy and the follow-up will be carried out from the second trimester of pregnancy until the children are 6 years old, the age at which the diagnosis of neurodevelopmental disorders is possible.

Biological, clinical, social and environmental data will be collected at different stages of the follow-up and will be included into a large database.

A vizsgálat 2 csoportja

  • High-Risk Cohort

    High family risk cohort for recurrence of autism and other developmental disorders in siblings (have at least one child with a confirmed diagnosis of autism) Specific to the High Risk cohort: Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction. A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment. If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken

    Kezelés: Questionnaires, Biospecimen collection, Neurodevelopmental assessment visit és DNA collection

  • Low Risk Cohort

    Low family risk cohort for recurrence of autism and occurrence of other developmental disorders in siblings. The risk is comparable to the risk observed in the general population (do not have a child with autism, nor with other developmental disorders). Clinical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals, so that children in the "Low family risk" group benefit from the same evaluations as children in the "High family risk" group..

    Kezelés: Questionnaires, Biospecimen collection és Neurodevelopmental assessment visit

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Platform for the Prospective Mother-child Study of the Determinants of Autism Spectrum Disorder and Neurodevelopmental Disorders Neurodevelopmental Disorders
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2026. június 22.